CCM
VRDN icon

Cinctive Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Cinctive Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,480
Closed -$225K – 559
2026
Q1 		$225K Sell
11,480
-50,289
-81% -$1.49M 0.01% 344
2025
Q4 		$1.92M Buy
+61,769
New +$1.69M 0.1% 213
2024
Q4 		– Sell
-26,541
Closed -$604K – 496
2024
Q3 		$604K Sell
26,541
-20,707
-44% -$339K 0.03% 329
2024
Q2 		$615K Buy
47,248
+6,390
+16% +$88.5K 0.03% 342
2024
Q1 		$715K Sell
40,858
-310
-0.8% -$6.01K 0.03% 318
2023
Q4 		$897K Buy
+41,168
New +$650K 0.06% 261

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cinctive Capital Management's VRDN Position: Q2 2026 in Review

Cinctive Capital Management sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 11,480 shares — an estimated $225K sold.

Cinctive Capital Management first reported a position in VRDN in Q4 2023 and held it in 6 quarters. The position peaked at $1.92M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Cinctive Capital Management reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 11,480 Viridian Therapeutics shares in Q2 2026, an estimated $225K.
  • Cinctive Capital Management first reported a position in Viridian Therapeutics in Q4 2023 and held it in 6 quarters.
  • Cinctive Capital Management's Viridian Therapeutics position peaked at $1.92M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.